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Abstract
Background: The pharmacokinetics and pharmacodynamics of vaginal microbicides are typically assessed among sexually
abstinent women. However, the physical act of sex may modulate gel distribution, and preclinical studies demonstrate
seminal plasma interferes with the antiviral activity of several microbicides. This study compared the biological activity and
concentration of PRO 2000 in cervicovaginal lavage (CVL) collected in the absence or following coitus.
Methods: CVL samples were collected from ten heterosexual couples at baseline, after sex, after a single dose of 0.5% PRO
2000 gel and sex, and after gel application without sex. The impact of CVL on HIV-1 infection of TZM-bl cells and HSV-2
infection of CaSki cells was monitored by luciferase and plaque assay, respectively. PRO 2000 concentrations were measured
by fluorescence.
Results: CVL collected after PRO 2000 application significantly inhibited HIV-1 and HSV-2 (p=0.01). However, the antiviral
activity was reduced following sex and no significant protective effect was observed in postcoital CVL obtained in the
presence compared to the absence of PRO 2000 for HIV (p=0.45) or HSV-2 (p=0.56). Less PRO 2000 was recovered in
postcoital CVL, which, in conjunction with interference by seminal plasma, may have contributed to lower antiviral activity.
Conclusions: Postcoital responses to PRO 2000 differ from precoital measures and the results obtained may provide insights
into the clinical trial findings in which there was no significant protection against HIV-1 or HSV-2. Postcoital studies should
be incorporated into clinical studies before embarking on large-scale efficacy trials.
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Introduction
HIV prevention is a critical health priority. While vaccines hold
promise, approaches to elicit protective immune responses remain
elusive. Pre-exposure prophylaxis with orally administered anti-
retroviral drugs may prove effective, but there are substantial
concerns for toxicities associated with long-term exposure and the
risk for selecting resistant viral variants. Topically delivered drugs,
designated microbicides, offer distinct advantages because they
would limit the toxicities associated with systemic prophylaxis.
However, significant protection has yet to be achieved by this
approach. In two recently completed clinical trials, HIV
Prevention Trial Network (HPTN) 035, which was conducted
among 3087 women and Microbicides Development Program
(MDP) 301, which was conducted among 9385 women, no
protection in HIV or HSV-2 acquisition was observed among
women randomized to coitally-dependent intravaginal application
of PRO 2000 compared to placebo gel. While the HPTN 035 trial
showed a 30% (p=0.10) reduction in HIV in the 0.5% PRO 2000
compared to placebo gel arm, [1], the MDP trial results found no
evidence that PRO 2000 gel is not effective at preventing HIV
infection in women [2]. Specifically, in the primary efficacy
analysis, the rate of new HIV infection was 4.5 per 100 person-
years in the 0.5% PRO 2000 arm compared to 4.3 in the placebo
PLoS ONE | www.plosone.org 1 January 2010 | Volume 5 | Issue 1 | e8781arm. Notably, the MDP trial initially also included a 2% PRO
2000 gel arm, which was prematurely discontinued by an
independent data safety monitoring committee in February,
2008 because it would have little chance to show effectiveness;
the HIV infection rate in the 2% PRO 2000 arm was 4.7 per 100
person-years compared with 3.9 in placebo arm at that time,
though the difference was not statistically significant (p=0.239).
Moreover, none of the previous microbicide clinical trials with
other candidate drugs has demonstrated significant protection
against HIV and in some trials, higher rates of infection were
observed in the treatment compared to the placebo arm [3,4,5].
Reduced potency against R5 viruses and difficulties with
adherence to coitally-dependent products may have contributed
to the lack of efficacy observed with some products. In addition, in
vitro studies have shown that low concentrations of polyanions can
increase HIV infection [6]. Furthermore, the induction of
inflammatory responses and interference with innate mucosal
defenses may have contributed to the enhanced HIV acquisition
rates observed with nonoxynol-9 (N-9) and cellulose sulfate [7,8].
Additional factors that may impact microbicide efficacy are
sexual activity and semen. Preclinical studies of microbicides are
typically performed in culture systems or animal models with virus
introduced in buffer. These models do not reflect what occurs
during heterosexual transmission, where female genital tract
secretions, semen and coitus may modulate microbicide activity.
Some microbicides show reduced antiviral effects in culture when
virus is introduced in seminal plasma (SP) [9,10]. For example,
cervicovaginal lavage (CVL) obtained 1 hour post-application of
0.5% PRO 2000 gel inhibited HSV-2 infection ,1000-fold when
cells were infected with virus diluted in buffer, but by only 20-fold
when virus was diluted in pooled human SP [10]. Mechanistic
studies demonstrated that SP proteins competitively inhibited the
binding of PRO 2000 to the HSV-2 envelope [10]. SP also
interferes with the in vitro anti-HIV activity of some microbicides,
although the mechanism(s) have not yet been elucidated and the
extent of interference may be less than that observed with HSV-2
[9,11]. Not only may semen interfere with antiviral activity, but
semen-derived amyloid fibrils may enhance HIV infectivity,
although the clinical relevance of these in vitro observations have
not been substantiated [12].
Together, these observations suggest that the pharmacokinetics
(PK) and pharmacodynamics (PD) of microbicides may differ
following coitus. Thus, we performed an open-label study among
10 monogamous couples to determine the concentration of drug
and antiviral activity in CVL obtained after intravaginal
application of a single dose of 0.5% PRO 2000 gel in the absence
of or following sexual intercourse. This study was completed prior
to the release of the MDP301 results.
Methods
Ethics Statement
The study was approved by the Albert Einstein College of
Medicine Institutional Review Board (IRB) and the NIAID
Division of AIDS Prevention Science Review Committee; all
participants provided written informed consent.
Participants
Ten healthy couples were recruited between July 2008 and June
2009. Inclusion criteria included use of any form of contraception
except condoms or a diaphragm and couples had to be at low risk
for sexually transmitted infections (STI) (no STI in previous six
months, no history of intravenous drug use, and in a mutually
monogamous relationship for at least six months). Participants
were excluded for pregnancy, breastfeeding, menopause, vasecto-
my, HIV, genitourinary infection, vaginitis or abnormal Pap test.
Couples were also excluded if they were discordant with respect to
HSV-1 or HSV-2 serostatus.
At screening, female participants had urine collected for
microscopy and culture and blood was obtained for pregnancy
testing. A gynecological examination was performed for detection
of bacterial vaginosis (BV), Trichomonas vaginalis, and Candida species
and a Pap test was collected. CVL was performed by washing the
cervix and posterior fornix with 10 ml of normal saline (pH ,5.5).
Male subjects had a genital exam and urinalysis. All subjects had
nucleic acid amplification testing of urine for Neissseria gonorrhoeae
and Chlamydia trachomatis (Gen-Probe, Inc., San Diego, CA) and
blood was collected for HIV ELISA, HIV-1 RNA by bDNA
(Siemens Healthcare Diagnostics, Deerfield, IL), syphilis (rapid
plasma reagin test), and serotype specific antibodies for HSV-1
and HSV-2 (HerpeSelect, Focus Diagnostics, Cypress, CA).
Subsequent study visits were conducted 3–5 days apart and
participants were instructed to abstain from sex and ejaculation for
48 hours prior to each visit. At the second visit, couples were
instructed to have vaginal-penile intercourse without using a
condom either in a private room in the Clinical Research Center
(CRC) or at home, if they lived in close proximity. Women were
asked to return to the CRC for collection of a postcoital CVL
within 2 hours. At the third visit, the study clinician applied a
single dose of 0.5% PRO 2000 gel intravaginally, each couple was
again instructed to have sex without using a condom and women
were asked to return within 2 hours for a lavage. Only the females
returned for the final visit at which a single dose of 0.5% PRO
2000 gel was applied intravaginally. The subject was then
permitted to ambulate and return for collection of CVL at a time
consistent with lavage collection at Visit 3.
Vaginal pH was measured from a swab of the lateral vaginal
wall before and after coitus at Visit 2, before PRO 2000 gel
application and after coitus at Visit 3 and before and after gel
application at Visit 4 (Whatman pH paper, pH 3.8–5.5 and
pHydrion paper, pH 6.0–9.5) (Couples 4–10). A swab of the
vaginal wall was obtained following intercourse at Visits 2 and 3 to
test for the presence of semen using an antibody immunoassay that
detects p30, a glycoprotein produced by the prostate (Abacus
Diagnostics, West Hills, CA).
Study Drug
PRO 2000 gel is an aqueous gel containing 0.5% (w/w) PRO
2000 packaged in single dose (2-mL) lacquer-lined aluminum
tubes and provided by Endo Pharmaceuticals, Chadds Ford, PA.
Unformulated drug was also obtained from Endo.
CVL and SP Samples
CVL were transported to the laboratory on ice and clarified by
centrifugation at 700 rpm for 10 minutes at 4uC. Supernatants
were divided into aliquots and stored at 280uC. The protein
concentration (Pierce BCA) and pH (ColorpHast, pH 2–9, EMD
Chemicals) were determined.
HIV-Infection Assays
HIV-1BaL was grown as described and was selected because R5
viruses predominate following sexual transmission [13,14]. TZM-
bl cells were cultured in 96 well dishes overnight as described [15].
The cells were infected with HIV-1BaL (10
3 TCID50) mixed 1:1
with CVL or control buffer (normal saline containing 1.5 mg/mL
bovine serum albumin). After 48 hour incubation at 37uC, the
inoculum was removed by washing, cells were lysed and luciferase
activity was measured in relative light units (RLU) [14]. Mock
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in triplicate in two independent experiments.
To generate dose response curves to PRO 2000 under
conditions that simulate the postcoital CVL, TZM-bl cells were
infected with HIV-1BaL diluted in media alone or in media
containing pooled SP and mixed 1:1 with serial dilutions of
unformulated PRO 2000 diluted in pooled CVL. The pooled
CVL and SP were generated from 3–5 healthy volunteers and
processed as previously described [10]. Cell proliferation was
assessed in uninfected plates treated with the CVL and pooled SP
for 48 h using the CellTiter 96 cell-proliferation assay (Promega,
Madison, WI) [14].
Anti-HSV Activity of CVL
CaSki (human cervical epithelial) cells were infected with serial
10-fold dilutions of HSV-2(G) (0.01–1000 pfu/cell) mixed 1:1 with
each CVL or control buffer [16]. After 1-h incubation at 37uC, the
cells were washed and overlaid with fresh medium. Plaques were
counted after 48 hours by immunoassay [17]. Wells with plaques
ranging from 20 to 150 were used to calculate the viral titer (PFU/
ml). All samples were tested in duplicate in two independent
experiments.
Measurement of PRO 2000 Levels in CVL
The concentration of PRO 2000 in CVL supernatants was
determined using a previously described fluorescence assay [16].
In brief, a standard stock was established by diluting 0.5% PRO
2000 gel into control CVL to a final concentration of 200 mg/ml
and then serial 2-fold dilutions were generated for standards (range
0.1–100 mg/ml). 20 ml of each standard or test CVL samples were
combined with 620 mg/ml of buffer (0.1 M sodium phosphate,
pH 7.0, containing 0.1 M SDS) and fluorescence was measured
(excitation 330 nm, emission 355 nm) in a fluorescence spectro-
photometer (Perkin-Elmer model LS-5). The concentration of
PRO 2000 in the samples was interpolated from the generated
calibration curve.
Statistical Analysis
GraphPad Prism (version 4; GraphPad Software) and SPSS for
Windows (version 17) were used for statistical analyses. The
antiviral activity in CVL was compared with Wilcoxon signed-
rank tests to account for non-Gaussian distributions. Spearman’s
correlation coefficients were calculated to analyze correlations
between PRO 2000 concentrations and mean antiviral activity in
CVL. All tests for statistical significance were two sided, with p
values#0.05 considered significant.
Results
Subjects
Twenty heterosexual couples were assessed for eligibility. Ten
couples were excluded; six had discordant HSV serologies, one
female developed a genital herpes recurrence, one had an
abnormal Pap test, and two had discordant HSV serologies and
abnormal Pap tests. All enrolled participants completed the study
as planned. Only three adverse events were reported, none of
which was considered medically significant. One subject noted
vaginal itching immediately following gel insertion; one with a
prior history of intermenstrual bleeding noted vaginal spotting,
and one developed rhinorrhea during the study. All participants
were HSV-2 seronegative.
Demographics and clinical data for the enrolled couples are
detailed in Table 1. The time between gel application and CVL
collection for Visits 3 and 4 were similar and ranged between 40–
105 minutes. Semen was detected in vaginal swabs obtained
following intercourse (Visits 2 and 3) in all participants by a p30
immunoassay. The median (IQR) pH was significantly higher in
the vaginal swab (p=0.02) collected following sex (7.90 (6.90,
8.00)) compared to in the absence of sex (4.60 (4.50, 5.00)). PRO
2000 did not noticeably affect the vaginal pH (Table 1). In
addition, the median (IQR) protein concentration (mg/ml) was
significantly higher in postcoital CVL (Visits 2 and 3; 714 (339,
5091) and 720 (223, 6339)) compared to baseline CVL (296 (59,
492)) (p,0.01) (Table 1). Notably, the protein concentration was
lower in the post-PRO 2000 (Visit 4; 39 (23, 188) CVL compared
to baseline CVL (p=0.014). The drug did not interfere with the
assay as no differences in protein concentrations were observed if
the standards were diluted in PBS or in PBS containing PRO 2000
gel (final concentration 100 mg/ml) (not shown). The concentra-
tions may be lower in the post-gel CVL because the gel binds to
mucosal proteins or cells, interfering with protein recovery by
lavage.
Anti-HIV Activity Is Lower in Post-Gel CVL Obtained
following Coitus
CVL collected following a single dose of PRO 2000 gel in the
absence of coitus significantly inhibited HIV infection compared
to baseline CVL (Visit 4 vs. Visit 1; p=0.01) (Fig. 1, upper panel
and Table 2). However, the inhibitory activity of post-gel CVL was
significantly less following sex (Visit 4 vs. Visit 3; p=0.02) (Fig. 1,
middle panel) and there was no significant protection provided by
post-gel, postcoital CVL (Visit 3) compared to postcoital CVL
(Visit 2) (p=0.45) (Fig. 1, lower panel). There was, however,
substantial intercouple variation.
Notably, HIV infection was an order of magnitude lower
(p=0.2) (Fig. 2) when cells were infected in the presence of
baseline CVL (Visit 1) compared to control buffer, which
presumably reflects the endogenous activity of genital tract
secretions. However, HIV infection was modestly higher (though
not statistically significant, p=0.17) in the presence of postcoital
compared to baseline CVL (Visit 2 vs. Visit 1).
Reduction in Anti-HSV Activity in Post-Gel CVL Obtained
following Coitus
Parallel studies were conducted with HSV-2. In the absence of
coitus, the post-gel CVL (Visit 4) significantly inhibited infection
(p=0.01) and reduced viral titer ,1000-fold compared to baseline
CVL (Visit 1) (Fig. 3, upper panel and Table 2). However, there
was significantly lower protective activity in CVL obtained
following coitus (Visit 4 vs. Visit 3, Fig. 3, middle panel)
(p=0.01) and no significant difference in the antiviral activity of
post-gel, postcoital CVL (Visit 3) compared to postcoital CVL
(Visit 2) (p=0.56; Fig. 3, lower panel). Notably, baseline CVL
(Visit 1) significantly reduced HSV-2 plaque formation compared
to control buffer and this endogenous activity persisted following
coitus (p=0.01; Fig. 4). None of the CVL samples had any impact
on CaSki or TZM-bl cell viability (data not shown).
PRO 2000 Concentrations
No significant differences were observed in the standard curves
generated from serial dilutions of PRO 2000 gel mixed with
pooled CVL or with a mixture of pooled CVL and SP (CVL and
SP obtained from healthy donors, final concentration 20% SP),
indicating that SP does not interfere with detection of PRO 2000.
Notably, significantly lower drug was detected in CVL obtained
following coitus (median (IQR) 14 (3, 27)) compared to CVL
obtained in the absence of coitus (28 (22, 110) (p=0.035; Table 1)
Postcoital Activity of PRO2000
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2000 (r=0.48, p=0.03 for both HIV and HSV-2). Thus, lower
antiviral activity in postcoital CVL could be attributed, at least in
part, to lower PRO 2000 concentrations. Whether the drug is
redistributed within the genital tract, bound to semen, more
difficult to recover because of physical changes to the gel or lost
due to leakage cannot be differentiated. Only a few women
reported leakage and these self-reports did not correlate with the
concentration of PRO 2000 detected in CVL. In addition,
variability in the volume of ejaculate may have impacted the
amount of drug or genital tract secretions recovered in postcoital
CVL.
Table 1. Demographic and clinical data from 10 couples.
Couple Gender; Age; Race HSV-1 Serostatus Visit #
Time CVL
(min)*
Vaginal pH
before & after
sex or gel
[Protein] in CVL
(mg/ml)
[PRO 2000] in CVL
(mg/ml)
1 F; 27; White Neg 1 298
M; 32; White Neg 2 40 297
3 65 340 3.7
4 90 100 104.6
2 F; 31; Hawaiian Neg 1 604
M; 31 Hawaiian Neg 2 50 962
3 65 603 16.2
4 65 174 28.25
3 F; 30; Asian Pos 1 24
M; 32; Asian Pos 2 35 95
3 90 105 3.7
4 105 31.3 18.45
4 F; 29; Asian Pos 1 505
M; 26; White Pos 2 20 4; 8 494
3 60 4.5; 8 818 47.3
4 65 4.5; 5 16 58.55
5 F; 25; White Pos 1 478
M; 38; White Pos 2 35 5; 8 5524
3 70 5; 8 3976 12.1
4 70 5.5; 5 29 126.1
6 F; 23; Asian Neg 1 93
M; 25; White Neg 2 50 5; 8 6276
3 100 5; 8 5679 59.95
4 100 5; 4.5 32 151.05
7 F; 30; White Neg 1 0.5
M; 31; White Neg 2 45 4.5; 7.5 736
3 65 4.5; 6.5 92 0.85
4 60 4.5; 4 46 28.5
8 F; 26; White Neg 1 112
M; 28; White Neg 2 25 4.5; 8 4658
3 40 4.5; 7.8 6339 16.4
4 40 4.5; 4.5 85 22.9
9 F; 25; Mixed Neg 1 294
M; 24; White Neg 2 60 5; 7 693
3 65 5; 6.8 1928 20.05
4 65 4.9; 5.5 202 0
10 F; 25; White Neg 1 378.5
M; 26; White Neg 2 45 4.5; 6.4 379.8
3 55 4.7; 6.4 621.7 1.65
4 65 4.6; 3.5 236.3 23.95
F, female; M, male; min, minutes.
*Time (minutes) between intercourse and CVL collection for Visit 2 and time after gel application of CVL collection for Visits 3 and 4.
doi:10.1371/journal.pone.0008781.t001
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reduction in antiviral activity. For example, ,50 mg/ml PRO
2000 was recovered in Visit 3 CVL from Couples 4 and 6, but
little or no antiviral activity was detected, suggesting that SP
interferes with the antiviral activity of PRO 2000 or enhances the
infectiousness of virus. We previously published that PRO 2000
loses anti-HSV activity when virus is introduced in SP [10]. These
in vitro studies were extended, focusing on anti-HIV activity. TZM-
bl cells were incubated with serial 2-fold dilutions of PRO 2000
mixed in pooled CVL and infected with virus in media or in media
containing 5% pooled SP. Higher concentrations of pooled SP
(.12.5%) were cytotoxic when left in culture for 48 h (not shown).
In the absence of SP, PRO 2000 completely inhibited HIV
infection at a concentration less than 12.5 mg/ml, but .100 mg/
ml was required to achieve complete protection when 5% SP was
present (Fig. 5). The addition of 5% SP had little effect on HIV
infectivity as the RLU were similar in the absence or presence of
SP when no PRO 2000 was added.
Discussion
This is the first study to evaluate the PK and PD of a candidate
microbicide following coitus and clearly demonstrates that both
differ significantly from results obtained in the absence of sexual
intercourse. In addition to the significantly diminished antiviral
activity (PD) and lower concentrations of PRO 2000 (PK),
postcoital CVL had higher pH (mean 5.99 and 5.94 for visits 2
and 3, respectively) compared to CVL obtained in the absence of
sex (pH 4.75 and 4.65 for visits 1 and 4, respectively). The
Figure 1. Loss in the anti-HIV activity in CVL collected
following a single application of PRO 2000 gel in the absence
or following coitus. TZM-bl indicator cells were exposed to 10
3
TCID50 HIV-1BaL in the presence of each CVL sample and after 48 h
incubation, the cells were lysed and infection monitored by luciferase
assay. Results are mean RLU obtained from 2 independent experiments,
each conducted in triplicate. The upper panel shows results for each
subject for Visit 1 (baseline) versus Visit 4 (post-gel), middle panel for
Visit 4 (post-gel) versus Visit 3 (post-gel and postcoital) and lower panel
for Visit 2 (postcoital) versus Visit 3 (post-gel and postcoital).
doi:10.1371/journal.pone.0008781.g001
Table 2. Viral infection in presence of each CVL or control
buffer.
Visit
HIV Infection RLU610
3
Median (IQR)*
HSV-2 Infection PFU/
ml610
3 Median (IQR)*
Control buffer 172 (115, 222) 28,000 (13,625, 66,625)
Visit 1 (Baseline) 19.1 (8.2, 55.7) 10,150 (7138, 22,088)
Visit 2 (Postcoital) 60.0 (10.6, 165.8) 11,275 (6913, 15,950)
Visit 3 (Post-gel;
postcoital)
15.7 (4.6, 58.3) 10,750 (1413, 34,475)
Visit 4 (Post-gel) 2.3 (2.1, 5.0) 8.35 (2.56, 58.38)
*IQR interquartile range.
doi:10.1371/journal.pone.0008781.t002
Figure 2. Endogenous anti-HIV activity in CVL collected in the
absence or following coitus. TZM-bl cells were infected with 10
3
TCID50 HIV-1BaL in the presence of Visit 1 (baseline) or Visit 2 (postcoital)
CVL or control buffer (saline with 1.5 mg/ml bovine serum albumin).
Mock infected cells were included as controls. Results are mean RLU
obtained from 2 independent experiments, each conducted in
triplicate.
doi:10.1371/journal.pone.0008781.g002
Postcoital Activity of PRO2000
PLoS ONE | www.plosone.org 5 January 2010 | Volume 5 | Issue 1 | e8781postcoital CVL samples also had significantly greater protein
concentrations compared to samples obtained in the absence of
sex (Table 1). However, it is unlikely that these differences
contributed to the differences in antiviral activity. No differences in
the antiviral activity of PRO 2000 were observed across a broad
pH range in vitro [18]. Moreover, a 1:5 dilution of pooled seminal
plasma (protein concentration ,6 mg/ml) had little effect on viral
infection [10].
The extent of antiviral activity and the optimal distribution of
drug required for protection are unknown. The CVL may
underestimate the total amount of drug found in the genital tract,
some of which may have been lost in the cell pellet during
centrifugation, adherent to epithelial cells within the genital tract,
or inaccessible to lavage. In addition, drug distribution to non-
target cells, could also result in drug dilution and decreased
efficacy. Even at Visit 4, only a small percentage of administered
PRO 2000 was recovered. However, the unbound drug may be
most important. The primary mechanism by which PRO 2000
inhibits HIV infection is binding to viral gp120, although some
activity may be attributed to binding to CD4 receptors on target
immune cells [19]. If during sex, drug is redistributed, bound to
cells in the ejaculate (which could include HIV-infected cells) or to
target cells in the genital tract, it could provide some anti-HIV
activity, although no protection was observed in the MDP301 trial.
In contrast, redistribution of PRO 2000 might further diminish
any impact against HSV-2, as infection likely occurs closer to the
introitus (or outside the vagina) and the drug acts primarily by
binding to the HSV-2 envelope glycoprotein B to competitively
inhibit viral attachment and entry [18].
Not only did sexual intercourse result in a reduction in PRO
2000 recovered in CVL, but the in vitro data (Fig. 5 and [10])
suggest that SP interfere with antiviral activity. Even when the
PRO 2000 concentrations in postcoital CVL (Visit 3) were similar
to the concentration measured in non-postcoital samples (Visit 4)
as observed with Couple 4, for example, the antiviral activity was
lower.
Important limitations of this study are the single dose design,
absence of a placebo gel group, reliance on CVL specimens alone,
and small sample size. A single dose may underestimate the
Figure 3. Loss in the anti-HSV activity in CVL collected
following PRO 2000 gel application in the absence or following
coitus. CaSki cells were infected with serial 10-fold dilutions of HSV-
2(G) mixed with each CVL sample. After incubation for 2 h, the
inoculum was removed by washing and the cells were overlaid with
fresh media. Infection was monitored by counting plaques after 48 h.
Results are viral titer (pfu/ml) calculated from 2 independent
experiments where each sample was tested in duplicate. The upper
panel shows results for each subject for Visit 1 (baseline) versus Visit 4
(post-gel), middle panel for Visit 4 (post-gel) versus Visit 3 (post-gel and
postcoital) and lower panel for Visit 2 (postcoital) versus Visit 3 (post-gel
and postcoital).
doi:10.1371/journal.pone.0008781.g003
Figure 4. Endogenous anti-HSV activity in CVL collected in the
absence or following coitus. CaSki cells were infected with HSV-2(G)
in the presence of Visit 1 (baseline) or Visit 2 (postcoital) CVL or control
buffer. Results are presented as viral titer (pfu/ml) obtained from 2
independent experiments, each conducted in duplicate.
doi:10.1371/journal.pone.0008781.g004
Postcoital Activity of PRO2000
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genital tract following repeated applications. In addition, differ-
ences in the duration of intercourse, ejaculate volume or
composition may have contributed to variability in antiviral
activity detected in postcoital samples. The addition of biopsy
samples to CVL collection would provide information regarding
drug distribution. Challenging biopsy samples ex vivo with HIV
would be especially critical for evaluating microbicides that act
intracellularly, such as tenofovir or dapivirine. However, the
number, size, and site of sampling will require optimization as
there is variability in the infectivity of biopsy tissue.
Although this study was not designed to evaluate endogenous
antiviral activity in genital tract secretions, baseline CVL (Visit 1)
inhibited both HIV and HSV-2, which is consistent with prior
studies [20,21,22]. Notably, the anti-HIV activity was diminished
when experiments were conducted with postcoital CVL (Visit 2),
suggesting interference with the endogenous anti-HIV activity.
Possibly, the alkaline pH or specific enzymes and proteases in
semen inactivate, degrade, or interfere with protective immune
mediators. In contrast, the anti-HSV-2 activity persisted in
postcoital CVL (Visit 2). Differences in the viscosity between the
control buffer and CVL samples may have contributed to the
endogenous antiviral activity, although most of the mucous pellets
with the cells during centrifugation. In addition, prior work
indicates that the anti-HSV activity correlates with the concen-
tration of specific antimicrobial proteins including defensins
(human neutrophil peptides 1–3) and lysozyme [22,23].
The endogenous anti-HSV activity in this study was less than
previously observed [22] and may reflect the fact that all women
who participated in this study were on hormonal contraception. In
a recently completed study, we found that the anti-HSV-2 activity
in CVL was reduced among women on hormonal contraception
compared to women not using hormonal contraception [23].
Larger studies are needed to fully evaluate the genital tract
environment both in the absence and following coitus.
In summary, this work demonstrates the feasibility and
importance of conducting postcoital studies. The current para-
digm of microbicide development should be modified to include
postcoital sampling following single and repeated dosing with both
active and placebo products and should be expanded to include
both CVL and biopsies to more fully define the PK and PD of lead
candidates prior to embarking on large-scale efficacy trials.
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